Marco Bandini1,2,3, Raisa S Pompe4,5, Michele Marchioni4,6, Emanuele Zaffuto7,8, Giorgio Gandaglia7,8, Nicola Fossati7,8, Luca Cindolo9, Francesco Montorsi7,8, Alberto Briganti7,8, Fred Saad4, Pierre I Karakiewicz4. 1. Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, MI, Italy. marco.bandini.zoli@gmail.com. 2. Vita-Salute San Raffaele University, Milan, Italy. marco.bandini.zoli@gmail.com. 3. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. marco.bandini.zoli@gmail.com. 4. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. 5. Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6. Department of Urology, SS Annunziata Hospital, "G. D'Annunzio" University of Chieti, Chieti, Italy. 7. Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, MI, Italy. 8. Vita-Salute San Raffaele University, Milan, Italy. 9. Department of Urology, ASL Abruzzo 2, Chieti, Italy.
Abstract
OBJECTIVES: Over the past decade, several systemic agents as docetaxel, cabazitaxel, sipuleucel-T, abiraterone and enzalutamide have improved overall survival (OS) in metastatic prostate cancer (mPCa) patients. However, to date the OS benefit was not demonstrated in population-based analysis. METHODS: Between 2004 and 2014, 19,047 men with de novo mPCa were identified within the Surveillance Epidemiology and End Results database. Median year of diagnosis resulted in two groups: historical (2004-2008) and contemporary (2009-2014). Due to potentially important differences according to year of diagnosis, we relied on propensity score matching. Propensity-score-matched Kaplan-Meier analyses and Cox regression models (CRMs) tested cancer-specific mortality (CSM) free survival and overall mortality (OM) free survival according to treatment period. RESULTS: The propensity-score-matched cohort consisted of 8596 patients with mPCa. Of those, 4298 (50.0%) were historical (2004-2008) and 4298 (50.0%) were contemporary (2009-2014). CSM free survival rates and OM free survival rate were 32 versus 36 months (p < 0.0001) and 26 versus 29 months (p < 0.0001) for, respectively, historical and contemporary patients. In multivariable CRMs, patients diagnosed in contemporary years had lower CSM (HR 0.88; CI 0.82-0.93) and OM (HR 0.88; CI 0.84-0.93) risks compared to historical counterpart (all p < 0.0001). CONCLUSION: This population-based study provides the first evidence of improved CSM free survival and OM free survival in patients with de novo mPCa since the introduction of several systemic agents for CRPC patients.
OBJECTIVES: Over the past decade, several systemic agents as docetaxel, cabazitaxel, sipuleucel-T, abiraterone and enzalutamide have improved overall survival (OS) in metastatic prostate cancer (mPCa) patients. However, to date the OS benefit was not demonstrated in population-based analysis. METHODS: Between 2004 and 2014, 19,047 men with de novo mPCa were identified within the Surveillance Epidemiology and End Results database. Median year of diagnosis resulted in two groups: historical (2004-2008) and contemporary (2009-2014). Due to potentially important differences according to year of diagnosis, we relied on propensity score matching. Propensity-score-matched Kaplan-Meier analyses and Cox regression models (CRMs) tested cancer-specific mortality (CSM) free survival and overall mortality (OM) free survival according to treatment period. RESULTS: The propensity-score-matched cohort consisted of 8596 patients with mPCa. Of those, 4298 (50.0%) were historical (2004-2008) and 4298 (50.0%) were contemporary (2009-2014). CSM free survival rates and OM free survival rate were 32 versus 36 months (p < 0.0001) and 26 versus 29 months (p < 0.0001) for, respectively, historical and contemporary patients. In multivariable CRMs, patients diagnosed in contemporary years had lower CSM (HR 0.88; CI 0.82-0.93) and OM (HR 0.88; CI 0.84-0.93) risks compared to historical counterpart (all p < 0.0001). CONCLUSION: This population-based study provides the first evidence of improved CSM free survival and OM free survival in patients with de novo mPCa since the introduction of several systemic agents for CRPC patients.
Authors: Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono Journal: Lancet Oncol Date: 2012-09-18 Impact factor: 41.316
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Joseph M Unger; Dawn L Hershman; Diane Martin; Ruth B Etzioni; William E Barlow; Michael LeBlanc; Scott R Ramsey Journal: J Natl Cancer Inst Date: 2014-12-24 Impact factor: 13.506
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Anne-Michelle Noone; Kathleen A Cronin; Sean F Altekruse; Nadia Howlader; Denise R Lewis; Valentina I Petkov; Lynne Penberthy Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-12 Impact factor: 4.254
Authors: Margaret Peggy Adamo; Jessica A Boten; Linda M Coyle; Kathleen A Cronin; Clara J K Lam; Serban Negoita; Lynne Penberthy; Jennifer L Stevens; Kevin C Ward Journal: Cancer Date: 2016-10-26 Impact factor: 6.860
Authors: Bruno Nascimento; Eduardo P Miranda; Lawrence C Jenkins; Nicole Benfante; Elizabeth A Schofield; John P Mulhall Journal: J Sex Med Date: 2019-05-09 Impact factor: 3.802
Authors: Nellie N Nafissi; Heidi E Kosiorek; Richard J Butterfield; Cassandra Moore; Thai Ho; Parminder Singh; Alan H Bryce Journal: Cureus Date: 2020-11-14
Authors: Isaac E Kim; Thomas L Jang; Sinae Kim; David Y Lee; Daniel D Kim; Eric A Singer; Saum Ghodoussipour; Mark N Stein; Monish Aron; Marc A Dall'Era; Isaac Yi Kim Journal: Cancer Med Date: 2021-10-29 Impact factor: 4.452
Authors: Johann S de Bono; Christina Guo; Bora Gurel; Angelo M De Marzo; Karen S Sfanos; Ram S Mani; Jesús Gil; Charles G Drake; Andrea Alimonti Journal: Nat Rev Cancer Date: 2020-06-16 Impact factor: 60.716